JP2007512260A5 - - Google Patents

Download PDF

Info

Publication number
JP2007512260A5
JP2007512260A5 JP2006540130A JP2006540130A JP2007512260A5 JP 2007512260 A5 JP2007512260 A5 JP 2007512260A5 JP 2006540130 A JP2006540130 A JP 2006540130A JP 2006540130 A JP2006540130 A JP 2006540130A JP 2007512260 A5 JP2007512260 A5 JP 2007512260A5
Authority
JP
Japan
Prior art keywords
treatment
type
heart
hypertension
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006540130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007512260A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CH2004/000688 external-priority patent/WO2005051909A1/de
Publication of JP2007512260A publication Critical patent/JP2007512260A/ja
Publication of JP2007512260A5 publication Critical patent/JP2007512260A5/ja
Withdrawn legal-status Critical Current

Links

JP2006540130A 2003-11-28 2004-11-15 ｛Ｎ−［１−（Ｓ）−カルボアルコキシ−３−フェニルプロピル］−Ｓ−アラニル−２Ｓ，３ａＲ，７ａＳ−オクタヒドロインドール−２−カルボン酸｝化合物類の製造方法 Withdrawn JP2007512260A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH20382003 2003-11-28
PCT/CH2004/000688 WO2005051909A1 (de) 2003-11-28 2004-11-15 Verfahren zur herstellung von {n-[1-(s)-carbalkoxy-3-phenylpropyl]-s-alanyl-2s, 3ar, 7as-octahydroindol-2-carbonsäure}verbindungen

Publications (2)

Publication Number Publication Date
JP2007512260A JP2007512260A (ja) 2007-05-17
JP2007512260A5 true JP2007512260A5 (enExample) 2007-12-06

Family

ID=34624414

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006540130A Withdrawn JP2007512260A (ja) 2003-11-28 2004-11-15 ｛Ｎ−［１−（Ｓ）−カルボアルコキシ−３−フェニルプロピル］−Ｓ−アラニル−２Ｓ，３ａＲ，７ａＳ−オクタヒドロインドール−２−カルボン酸｝化合物類の製造方法

Country Status (4)

Country Link
US (1) US20070135513A1 (enExample)
EP (1) EP1689711A1 (enExample)
JP (1) JP2007512260A (enExample)
WO (1) WO2005051909A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007003947A2 (en) * 2005-07-05 2007-01-11 Cipla Limited Process for the synthesis of the ace inhibitor trandolapril
US7943655B2 (en) 2006-04-05 2011-05-17 Universitat Zurich Polymorphic and pseudopolymorphic forms of trandolaprilat, pharmaceutical compositions and methods for production and use
CA2768239A1 (en) 2009-07-16 2011-01-20 Abbott Laboratories Processes for the synthesis of (2s, 3ar, 7as)-octahydro-1h-indole carboxylic acid as an intermediate for trandolapril
CN109689611B (zh) 2016-07-21 2021-09-28 株式会社钟化 有机化合物的制造方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ202903A (en) * 1981-12-29 1988-01-08 Hoechst Ag 1-- pe pyrrol-2-yl-carboxylic acid derivatives and pharmaceutical compositions
JPS6248696A (ja) * 1985-08-27 1987-03-03 Kanegafuchi Chem Ind Co Ltd Ｎ−〔１（ｓ）−エトキシカルボニル−３−フエニルプロピル〕−ｌ−アラニル−ｌ−プロリンの製造法
US6541635B1 (en) * 2002-03-29 2003-04-01 Everlight Usa, Inc. Method for producing angiotensin converting enzyme inhibitor

Similar Documents

Publication Publication Date Title
LTC1562603I2 (lt) Nauji vaistai, skirti lėtinių obstrukcinių plaučių ligų gydymui
JP2004210767A5 (enExample)
NO2018029I2 (no) Kombinasjonen alogliptin og metformin, hver eventuelt i form av et farmasøytisk akseptabelt salt derav
NO20081016L (no) Nye 1-aryl-3-azabicyklo(3.1.0)heksaner, fremstilling og bruk for å behandle nevropsykiatriske lidelser
JP2003503454A5 (enExample)
NO2017047I1 (no) Tofacitinib, evt. i form av et farmasøytisk akseptabelt salt, inkludert citratsalt
LT2878297T (lt) Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai
IS2722B (is) 1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum
JP2007522094A5 (enExample)
JP2007514005A5 (enExample)
NO20035496D0 (no) Substituerte sulfonamidforbindelser, fremgangsmåte for deres anvendelse sommedikament til behandling av CNS-forstyrrelser, overvekt og typeII-diabetes
JP2007523178A5 (enExample)
EP1363625A4 (en) COMBINATIONS OF DRUGS (eg, BENZIMIDAZOLE AND PENTAMIDINE) IN THE TREATMENT OF NEOPLASTIC DISORDERS
NO2014030I2 (no) en kombinasjon av rilpivirine eller et farmasøytisk akseptabelt salt av rilpivirine innbefattende hydroklorid-saltet av rilpivirine, og emtricitabine.
JP2007520565A5 (enExample)
ATE469131T1 (de) Sulfonamidderivate, ihre herstellung und ihre therapeutische anwendung
IL189500A (en) 4, 2-Diaminopyrimidines are preserved in position 5, containing pharmaceutical preparations and using them to prepare a drug for the treatment of 3x2p receptor mediated diseases and 2/3 x2p
WO2007112014A3 (en) New therapeutic combinations for the treatment of depression
CN1545409A (zh) 二苯乙烯类化合物在制备用于治疗和预防糖尿病或与逆转录病毒有关疾病的药物中用途
JP2006511520A5 (enExample)
AP2359A (en) Sulfonamide derivatives for the treatment of diseases.
JP2007536277A5 (enExample)
JP2003526626A5 (enExample)
JP2005509503A5 (enExample)
AP2006003688A0 (en) 1,3-dioxane derivatives and analogues thereof useful in the treatment of I.A obesity and diabetes